Tvardi Therapeutics, Inc. (TVRD)
TVRDNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.17
+0.0050 (+0.43%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $15.74m
- P/E
- –
- EPS, last 4 quarters
- $-2.79
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.7729 to $5.69
- Average volume
- –
- Previous close
- $1.17
Analysts
6 coveringBuy5 buy, 0 hold, 1 sell
Targets a year out average $8.17, +598.3% from here
Earnings
next estimate $-0.5100Next report
Sep 2025
+28.9%
Dec 2025
-41.8%
Mar 2026
-12.3%
Jun 2026
-6.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$5.94m | -$7.59m | -$7.05m | -$6.63m |
| Net income | -$5.53m | -$7.28m | -$6.80m | -$6.46m |
News
8 latest- Tvardi Q3 Loss Widens On Higher Clinical Costs; Liver Cancer Data Due Early Q1 2027 RTTNews · 22 hours ago
- Tvardi Therapeutics Consensus Price Target Increased by 11.76% to $9.69Fintel · Sep 15, 2026
- TVRD Stock Rallies 149% So Far This Week: Here's What You Should KnowZacks · Jul 9, 2026
- Tvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study RTTNews · Jul 7, 2026
- Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor? RTTNews · Jun 29, 2026
- Tvardi Therapeutics Narrows FY25 Loss, Prepares For Key STAT3 Clinical Readouts In 2026 RTTNews · Apr 1, 2026
- Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks · Nov 18, 2025
- Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock NowZacks · Oct 28, 2025
The company
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in gastrointestinal (GI) diseases pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma ( NCT05440708 ). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- tvarditherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.